Swiss informatics firm Sophia Genetics has moved into liquid biopsies with an update to its SOPHiA AI system, changing how clinicians treat some cancers.
Hospitals in Morocco, Cameroon, and South Africa recently adopted its SOPHiA artificial intelligence offering, the firm's first crop of African customers.
The partnership aims to improve cancer molecular profiling by combining Horizon's HDx reference standards with Sophia's artificial intelligence solution.
The companies will combine their respective technologies to provide an integrated analytical and next-generation sequencing sample preparation offering for cancer research.
In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.
